Advice

following an abbreviated submission:

ipilimumab (Yervoy®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.

SMC has previously accepted ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in previously untreated adult patients (No. 997/14) and in adults who have received prior therapy (No. 779/12).

Ipilimumab was accepted for use in previously untreated patients (No. 997/14) following a submission under the end of life and orphan process.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ipilimumab. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.

Download detailed advice68KB (PDF)

Download

Medicine details

Medicine name:
ipilimumab (Yervoy)
SMC ID:
SMC2094
Indication:
Treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated submission
Status
Accepted
Date advice published:
08 October 2018